# Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

> **NCT03068130** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 261 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Bardoxolone methyl

## Key facts

- **NCT ID:** NCT03068130
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-18
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 261 (ACTUAL)
- **Why stopped:** The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03068130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03068130, "Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03068130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*